The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia

First-line nilotinib in chronic myeloid leukemia is more effective than imatinib to achieve early and deep molecular responses, despite poor tolerability or failure observed in one-third of patients. The toxicity and efficacy of tyrosine kinase inhibitors might depend on the activity of transmembran...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Galimberti, Sara, Bucelli, Cristina, Arrigoni, Elena, Baratè, Claudia, Grassi, Susanna, Ricci, Federica, Guerrini, Francesca, Ciabatti, Elena, Fava, Carmen, D’Avolio, Antonio, Fontanelli, Giulia, Cambrin, Giovanna Rege, Isidori, Alessandro, Loscocco, Federica, Caocci, Giovanni, Greco, Marianna, Bocchia, Monica, Aprile, Lara, Gozzini, Antonella, Scappini, Barbara, Cattaneo, Daniele, Scortechini, Anna Rita, La Nasa, Giorgio, Bosi, Alberto, Leoni, Pietro, Danesi, Romano, Saglio, Giuseppe, Visani, Giuseppe, Cortelezzi, Agostino, Petrini, Mario, Iurlo, Alessandra, Di Paolo, Antonello
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5675690/
https://ncbi.nlm.nih.gov/pubmed/29152138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21406
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares